Silence Therapeutics to be acquired by Merck in $1.3 billion deal
FROM THE WIRE · FINANCE.YAHOO.COM
Silence Therapeutics' (SLN) US-listed shares soared Monday after the UK-based biotechnology company PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishMid-sized cross-border biotech acquisition that is driving the target's shares higher.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Silence Therapeutics' US-listed shares soared Monday.
- 02The UK-based biotech company will be acquired by Germany's Merck.
- 03The deal is valued at $1.3 billion.
NEWS IMPACT AND MARKET REACTIONChange from the reference price
Silence Therapeutics plc19.58 USDMarket closedtoday +125.58%Positive Merck & Co., Inc.143.67 USDMarket closedtoday -1.56%Neutral
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets